Blog - Page 5340 of 5383

TuesdayJul 25, 2006 12:17 pm

StockGuru Morning Alert: Yesterday Elgrande International (OTCBB: EGDI) – Up as much as 30.7%, Closing Up Almost 8% on Heavy Volume

StockGuru Alert: Yesterday… Elgrande International (OTCBB: EGDI) - Up as much as 30.7%, Closing Up Almost 8% on Heavy Volume Elgrande International, Inc. (OTCBB: EGDI) View the StockGuru Profile for Elgrande International (OTCBB: EGDI): http://www.stockguru.com/profiles/egdi/ We Invite you to Visit the All New StockGuru Blog! Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks. Click HERE to visit the Blog, or go to: http://stockguru.com/blog/ StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was…

TuesdayJul 25, 2006 12:14 pm

StockGuru News: Clearly Canadian Beverage Corporation (OTCBB: CCBEF) Significantly Improves Financial Position

Clearly Canadian Beverage Corporation (OTCBB: CCBEF) Clearly Canadian Significantly Improves Financial Position VANCOUVER, B.C.–July 25, 2006–CLEARLY CANADIAN BEVERAGE CORPORATION (OTCBB: CCBEF) is pleased to announce that on the heels of its recent financings and settlement of outstanding litigation, it is now, aside from regular trade payables, effectively debt free and has increased its current cash position to more than US $5.3 million. Brent Lokash, President of Clearly Canadian stated, “We now have a very strong financial foundation which could accelerate our efforts towards broadening distribution, increasing availability of our product lines, exploring all profitable alternatives related to our brand name…

TuesdayJul 25, 2006 12:09 pm

StockGuru News: Transnational Automotive Group and On The Go Technologies Group

Transnational Automotive Group (OTCBB:TAMG) TAMG Buses Arrive in Cameroon SEATTLE, WASHINGTON–(MARKET WIRE)–Jul 25, 2006 — Transnational Automotive Group, Inc. (OTC BB:TAMG.OB - News), today announced that the Company’s first 28 buses, under its Cameroon public transport contract, arrived at the port of Douala on 22 July and were unloaded from the cargo ship BBC Germany. Read full release here: http://stockguru.com/profiles/tamg/news.php On The Go Technologies Group (OTCBB: OGHC) On The Go Appoints GE IT Solutions and CompuCom Systems Veteran as Enterprise Division Sales Director CONCORD, Ontario, July 25 /PRNewswire-FirstCall/ — On The Go Technologies Group (OTC Bulletin Board: OGHC - News),…

TuesdayJul 25, 2006 11:58 am

StockGuru News: Mobile Ready Entertainment Corporation (OTC:MBRN) Closes Acquisition With Key2Travel Inc.

Mobile Ready Entertainment Corporation (OTC:MBRN) Mobile Ready Entertainment Corp. Closes Acquisition With Key2Travel Inc. MBRN Announces Close of Acquisition Transaction With Las Vegas Travel Entertainment Company STROUDSBURG, PA and LAS VEGAS, NV–(MARKET WIRE)–Jul 25, 2006 — Mobile Ready Entertainment Corp. (OTC: MBRN) is pleased to announce that it had signed and closed the definitive acquisition documents with Key2Travel Inc. in a deal that brings product, personnel and a good balance sheet to the Company. “Today represents one of the most significant steps in Mobile Ready’s formation,” said Josh Eikov, CEO of Mobile Ready Entertainment Corp. “Mobile Ready is now on…

MondayJul 24, 2006 11:56 am

StockGuru Blog: The Immune Response Vaccines — Clinical Trials for HIV Infections

IMNR - The Immune Response Corporation Clinical Studies With IR 103 IMNR’s clinical trial program is testing IR103 in drug-naïve HIV-infected individuals with HIV infection who do not meet the criteria for antiretroviral therapy. The objective is to determine if IR103 can delay disease progression and extend the time to starting antiretroviral therapy, mimicking the effect seen in long term non-progressing patients. IR103 is currently in two Phase II clinical trials with identical protocols. The two trials are known as IR111 (Canada/UK) and IR112 (Italy/France). The Phase I/II clinical trials began in 2004. IMNR completed a 49-patient Phase I/II five-arm,…

MondayJul 24, 2006 11:47 am

StockGuru News: IncreMental Advantage Initiates Coverage of The Immune Response Corporation with Price Target of $0.09 Per Share, Accumulate Rating

IncreMental Advantage Initiates Coverage of The Immune Response Corporation with Price Target of $0.09 Per Share, Accumulate Rating The Immune Response Corporation (OTCBB: IMNR) CARLSBAD, Calif.–(BUSINESS WIRE)–July 24, 2006–The Immune Response Corporation (OTCBB: IMNR - News) announced today that IncreMental Advantage, an equity research firm, has initiated coverage on the Company with an Accumulate rating, and a price target of $0.09 per share. The Immune Response Corporation’s product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by IncreMental’s highly experienced biotechnology analyst, Robert LeBoyer, who…

MondayJul 24, 2006 11:47 am

StockGuru News: Response Biomedical Corporation, China Wireless Communications, Cavico Corporation, Oxford Media, and Enterayon

Response Biomedical Corp. (OTCBB: RPBIF) & (TSX.V: RBM) Response Biomedical Completes US Distribution Network For RAMP Cardiovascular Products US Distributors include Cardio Medical Products, Kentec Medical, and LXU Healthcare VANCOUVER, July 24 /CNW/ - Response Biomedical Corporation (TSX-V: RBM, OTCBB: RPBIF), announced today that RAMP Cardiac Tests are now commercially available throughout the US through three exclusive regional distributors. Response Biomedical completed its US distribution network with the appointments of two additional exclusive regional US distributors: Kentec Medical, Inc. and Cardio Medical Products, Inc. Read full release here: http://stockguru.com/profiles/rpbif/news.php China Wireless Communications (OTCBB: CWLC) China Wireless Shareholder Update: Company Is…

MondayJul 24, 2006 11:47 am

StockGuru Blog: The Immune Response Vaccines — How They Work: Fight an Existing Disease Rather than Prevent Disease

IMNR - The Immune Response Corporation Immune Response Vaccines: The Immune Response vaccines differ from the conventional vaccines in that they are intended to stimulate a T-cell response with immune system cells that fight the antigen rather than an antibody response from the B-cells. IMNR’s products also differ in that they are therapeutic vaccines designed to fight an existing disease rather than to prevent a future one. Upon administration, the immune system will recognize the vaccine’s antigen and start a primary immune response. The B-cell portion of this response begins producing antibodies, which can be detected in the bloodstream after…

MondayJul 24, 2006 11:41 am

Elgrande International, Inc. has a Winning Team in Place

EGDI – Elgrande International, Inc.Elgrande International (OTCBB: EGDI) has a winning team in place. Michael F. Holloran - President and Chief Executive Officer Mr. Holloran brings to Elgrande a wealth of senior management experience spanning 32 years, including 22 years with the Beak International Group spearheading strategic corporate expansion into key international markets, primarily within Southeast Asia. He has served as a technical advisor to the Asian Development Bank, and the governments of Indonesia, Malaysia and the Philippines. He has held outside directorships, advisory board positions and committee memberships with several prominent North American institutions. He has a Masters degree…

MondayJul 24, 2006 11:36 am

StockGuru Welcomes The Immune Response Corporation (OTCBB: IMNR)

StockGuru Welcomes The Immune Response Corporation (OTCBB: IMNR) View the StockGuru Profile for The Immune Response Corporation: http://www.stockguru.com/profiles/imnr/ The Immune Response Corporation The Immune Response Corporation (OTCBB: IMNR) is a development stage biotechnology company with two products in Phase II clinical trials, one that targets multiple sclerosis (MS) and another that targets HIV/AIDS. These drugs act by stimulating the body’s immune system to slow or stop disease progression through mechanisms of action that differ from existing drugs. These diseases have large patient populations and substantial room for improvement over current therapies. If successful, these drugs could be used alone or…

Site Search

Company Search

StockGuru Morning Alert: Yesterday Elgrande International (OTCBB: EGDI) – Up as much as 30.7%, Closing Up Almost 8% on Heavy Volume

StockGuru News: Clearly Canadian Beverage Corporation (OTCBB: CCBEF) Significantly Improves Financial Position

StockGuru News: Transnational Automotive Group and On The Go Technologies Group

StockGuru News: Mobile Ready Entertainment Corporation (OTC:MBRN) Closes Acquisition With Key2Travel Inc.

StockGuru Blog: The Immune Response Vaccines — Clinical Trials for HIV Infections

StockGuru News: IncreMental Advantage Initiates Coverage of The Immune Response Corporation with Price Target of $0.09 Per Share, Accumulate Rating

StockGuru News: Response Biomedical Corporation, China Wireless Communications, Cavico Corporation, Oxford Media, and Enterayon

StockGuru Blog: The Immune Response Vaccines — How They Work: Fight an Existing Disease Rather than Prevent Disease

Elgrande International, Inc. has a Winning Team in Place

StockGuru Welcomes The Immune Response Corporation (OTCBB: IMNR)

Market Basics

Newsletter Publishers

Public Companies